Cite
Targeting TLR2/Rac1/cdc42/JNK Pathway to Reveal That Ruxolitinib Promotes Thrombocytopoiesis.
MLA
Yang, Shuo, et al. “Targeting TLR2/Rac1/Cdc42/JNK Pathway to Reveal That Ruxolitinib Promotes Thrombocytopoiesis.” International Journal of Molecular Sciences, vol. 23, no. 24, Dec. 2022, p. 16137. EBSCOhost, https://doi.org/10.3390/ijms232416137.
APA
Yang, S., Tang, X., Wang, L., Ni, C., Wu, Y., Zhou, L., Zeng, Y., Zhao, C., Wu, A., Wang, Q., Xu, X., Wang, Y., Chen, R., Zhang, X., Zou, L., Huang, X., & Wu, J. (2022). Targeting TLR2/Rac1/cdc42/JNK Pathway to Reveal That Ruxolitinib Promotes Thrombocytopoiesis. International Journal of Molecular Sciences, 23(24), 16137. https://doi.org/10.3390/ijms232416137
Chicago
Yang, Shuo, Xiaoqin Tang, Long Wang, Chengyang Ni, Yuesong Wu, Ling Zhou, Yueying Zeng, et al. 2022. “Targeting TLR2/Rac1/Cdc42/JNK Pathway to Reveal That Ruxolitinib Promotes Thrombocytopoiesis.” International Journal of Molecular Sciences 23 (24): 16137. doi:10.3390/ijms232416137.